Biostatistics and Mathematical Oncology Core Shared Resource ABSTRACT The Biostatistics and Mathematical Oncology Core (BMOC) provides City of Hope Comprehensive Cancer Center (COHCCC) members with access to expert statisticians and mathematicians who collaborate in basic, translational, clinical, and population research. The BMOC staff assist in the development of experimental designs, sample size estimation, statistical computing, data analysis, and interpretation of findings. In collaboration with investigators, they contribute to COHCCC publications and are a resource for new statistical methods in laboratory-based, clinical trial-based, and population-based research. Areas of expertise include: clinical trials; dose-escalation methods; survival analysis; cure models; preclinical studies, assays, bioassays, and toxicity screening; experimental and human genetics; gene expression (e.g., RNA-seq, microarray, NanoString), classification, prediction and signatures; 16s rRNA microbiome taxonomy; longitudinal and functional data analysis; mathematical modeling of cancer; extracting data from 3-dimensional tumor images; epidemiology and observational studies; adaptive questionnaires; SEER, TCGA, and other public databases; and extensive experience in statistics applied to cancer research involving immunology, cellular, and immune- directed therapy, and hematopoietic stem-cell transplantation. The BMOC is directed by Jeffrey Longmate, Ph.D., and draws upon the efforts of 20 faculty and staff who provide a wide range of expertise and play diverse roles in COHCCC research. Major changes have been made to the BMOC since the last review, including the recruitment of Russell Rockne, PhD, to lead a new mathematical oncology service line; the addition of Andrei Rodin, PhD, the Dr. Susumo Ohno Chair in Theoretical Biology; and the recruitment of two statisticians to support the Hematologic Malignancies Program. Operational changes include the appointment of statisticians to Disease Teams and major changes in statistical review procedures for the Protocol Review and Monitoring System. The primary goal of the Core is collaboration, development, and advancement of novel methods in the design, conduct, analysis, and publication of preclinical and clinical cancer-related research. The BMOC provides free short-term consulting to promote early statistical input. During the last finding period, BMOC faculty developed and published novel study designs and data analysis methods, which have been incorporated into Phase I and I/II clinical trials. The BMOC is supported by the Office of Shared Resources and overseen by the BMOC Advisory Committee, which includes the COHCCC Program Leaders. BMOC members work closely with the Integrative Genomics and Bioinformatics Core and the Analytical Pharmacology Core. In the last year, the BMOC supported 401 projects from 117 investigators, including 89 CC members, 48 of whom have peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-38
Application #
10059199
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Salgia, Ravi; Kulkarni, Prakash; Gill, Prakash S (2018) EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer 1869:128-137
Choi, Audrey H; O'Leary, Michael P; Lu, Jianming et al. (2018) Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer. Mol Ther Oncolytics 9:22-29
Kumar, B; Garcia, M; Weng, L et al. (2018) Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia 32:575-587
Zhou, Jiehua; Lazar, Daniel; Li, Haitang et al. (2018) Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics 8:1575-1590
Ding, Yuan Chun; Adamson, Aaron W; Steele, Linda et al. (2018) Discovery of mutations in homologous recombination genes in African-American women with breast cancer. Fam Cancer 17:187-195
Kurata, Jessica S; Lin, Ren-Jang (2018) MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs. RNA 24:966-981
Hardwick, Nicola R; Frankel, Paul; Ruel, Christopher et al. (2018) p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clin Cancer Res 24:1315-1325
Dietze, Eric C; Chavez, Tanya A; Seewaldt, Victoria L (2018) Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology. Am J Pathol 188:280-290
Kingsmore, Kathryn M; Vaccari, Andrea; Abler, Daniel et al. (2018) MRI analysis to map interstitial flow in the brain tumor microenvironment. APL Bioeng 2:
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096

Showing the most recent 10 out of 1396 publications